ClinicalTrials.gg
CompletedNCT03817684Updated Feb 18, 2025Results posted

Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects

A Phase 2 interventional study of BPN14770 and Placebo in Alzheimer's Disease, sponsored by Tetra Discovery Partners. Completed at 41 sites in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Tetra Discovery Partners (part of Shionogi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
353rd of 1,611
255 · median 73
Started
2019
with 117 others
Phase 2
360 of 1,942
50 open now
Registered
1,038th of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 353rd largest by enrollment of the 1,611 interventional ones that give a count, is one of 118 that started in 2019, is one of 360 in phase 2, and was the 1,038th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Disease

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females between the ages of 55 and 85 years with a clinical diagnosis of early stage AD, defined according to the following criteria assessed during Screening and at Baseline :

    1. Clinical Dementia Rating (CDR) score of 0.5 or 1, with Memory Box score of 0.5 or greater
    2. score of 20 or greater
    3. RBANS DMI score ≤ 85 Note: PET imaging for amyloid is not required for diagnosis, which will be made on clinical grounds.
  2. Currently receiving a stable (at least 2 months) dose regimen of donepezil or another cholinesterase inhibitor for treatment of Alzheimer's disease. Doses of these drugs may not be changed during the trial.

    Note: Memantine is not permitted during the trial and must be discontinued at least 3 weeks prior to Baseline.

  3. Modified Hachinski Ischemia score \< 4.
  4. (BMI) \< 38 kg/m2, inclusive, and body weight of >48 kg (105 pounds) at screening.
  5. Female subjects must be at least two years (subjected reported menopausal status), surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to first study drug administration), or willing to either (1) utilize hormonal plus one barrier method or (2) use two barrier methods of contraception (e.g. diaphragm and spermicide) from initial screening until one month after taking the final dose. An intrauterine device (IUD) is considered a barrier method of contraception in this study. Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to first study drug administration, or use at least one barrier method of birth control).
  6. Able to understand and comply with the study procedures, voluntarily agree to participate in this study, and provide written prior to start of any study-specific procedures.
  7. All subjects must have a caregiver who is willing and able to ensure compliance with study medications, visits, and study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any medical or neurological condition (other than early stage AD) that might be a contributing cause to the subject's cognitive impairment.
  2. History of stroke or multiple (>3 discreet episodes) (TIAs), severe head trauma with cognitive sequelae, uncontrolled seizures, or unexplained prolonged loss of consciousness (> 1 minute) during the past year.
  3. major psychiatric illness during the past 6 months.
  4. History of unstable angina, myocardial infarction, chronic heart failure, or clinically significant conduction abnormalities during the past year.
  5. Clinically significant liver or renal disease.
  6. Clinically significant abnormality, in the Investigator's judgment, in hematology, chemistry, or urinalysis.
  7. Positive serology results for surface antigen (HbsAg) or virus (HCV).
  8. Abnormal liver function test at the Screening Visit ( or alanine aminotransferase >2

    × the [ULN], or total >1.7 × ULN, based on appropriate age and gender normal values). Subjects may be re-screened once.

  9. Marked hypotension (systolic blood pressure [BP] ˂90 mmHg or diastolic BP ˂50 mmHg) or hypertension (systolic BP ˃160 mmHg or diastolic BP ˃100 mmHg) based on sitting values. O ut-of-range results may be repeated once at Screening, and eligibility must be confirmed at Baseline.
  10. Marked bradycardia (heart rate ˂45 beats per minute [bpm]) or tachycardia (heart rate ˃115 bpm) based on supine values. Out-of-range results may be repeated once at Screening, and eligibility must be confirmed at Baseline.
  11. Clinically important conduction abnormalities on ECG, or evidence or history of long syndrome based on supine ECG values obtained at Screening. Out-of-range results may be repeated once and eligibility confirmed at Baseline.
  12. Active gastric or duodenal ulcers or other diseases of the gastrointestinal tract that could interfere with absorption of study drug. Note: Subjects with a history of appendectomy or cholecystectomy may be enrolled.
  13. Active acute or chronic infectious diseases that would interfere with subject's participation in the study.
  14. Unable to discontinue centrally active medications (other than cholinesterase inhibitors), including memantine, psychotropic drugs other than SSRIs (which must have been stable for 2 months and remain stable throughout the study), sedative antihistamines or other centrally active medications with potential cognitive effects (e.g., CNS-penetrant beta blockers).
  15. Unable to discontinue moderate to strong inhibitors or inducers of , CYP2D6, or other cytochromes at least 14 days prior to the first dose of study drug. A complete listing of such inhibitors or inducers may be found in http://medicine.iupui.edu/clinpharm/ddis/main-table (Other prescription or non-prescription drugs such as antihypertensive or cholesterol lowering agents are allowed, if, in the Investigator's judgement, they would not interfere with the study medication or the cognitive testing.)
  16. A suicidal ideation intensity score of 3 or higher per screening Columbia Suicide Severity Rating Scale (CSSRS) assessment on Day 1 (Baseline) and/or any suicidal behavior within the past 28 days.
  17. History of chronic alcohol or other substance abuse, including marijuana, within the previous year prior to the Screening visit (per the current edition of the , 5th Edition: DSM-5), or regular (daily) consumption of alcohol exceeding two bottles of beer, or the equivalent amount of other forms of alcohol (1 serving = 12 oz beer, 5.0 oz wine, or 1.5 oz distilled spirits).
  18. Inability or unwillingness to comply with the protocol, including performing the cognitive function tests, or likely inability to complete the study.
  19. Participation in other clinical studies involving drug within the previous 30 days prior to the Screening Visit.
  20. Donation of blood within 4 weeks, or blood products within 2 weeks, prior to first study drug administration.
  21. History of clinically significant drug allergy that includes symptoms such as shortness of breath, rash, or edema.
  22. Clinically significant B12 deficiency within 12 months prior to Visit 1 (Screening). Participants on stable replacement therapy for a minimum of 3 consecutive months immediately prior to Visit 1 (Screening) may be included
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    BPN14770 10mg bid

    10 mg bid dose of the Drug BPN14770

    Drug: BPN14770

  • Experimental
    BPN 14770 25mg bid

    25mg bid dose of the Drug BPN14770

    Drug: BPN14770

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Drug BPN14770

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Repeatable Battery for the Assessment of Neurological Status- Delayed Memory Index (RBANS- DMI) at Week 13

    The RBANS is a brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory. It consists of 12 subtests, which yield 5 Index scores and a Total Scale score. Lower scores indicate worse performance on the test (and thus greater impairment). Scores for the RBANS DMI range from 40 (greater impairment) to 160 (improved function), with higher scores indicating improved function.

    Time frame: Baseline, Week 13

Secondary outcomes

  1. Change From Baseline in Repeatable Battery for the Assessment of Neurological Status (RBANS) Total Score at Week 13

    The RBANS is a brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory. It consists of 12 subtests, which yield 5 Index scores and a Total Scale score. Lower scores indicate worse performance on the test (and thus greater impairment). The RBANS total score ranges from 40 to 160, with higher scores indicating improved function.

    Time frame: Baseline, Week 13

  2. Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Total Score at Week 13

    The ADCS-ADL is an interviewer-administered informant-based scale where the informant (caregiver) responds to 23 activities of daily living questions about the participant. The questions range from basic to instrumental activities of daily living. The total score ranges from 0-78 and a higher score signifies greater functional ability.

    Time frame: Baseline, Week 13

  3. Change From Baseline in Mini-Mental State Exam (MMSE) Total Score at Week 13

    The MMSE consists of 11 items covering orientation, memory (recent and immediate), concentration, language and praxis. Total score ranges from 0 (severe cognitive impairment) to 30 (intact cognitive function), with lower scores indicating greater cognitive impairment. In participants with a diagnosis of AD, lower scores indicating worse disease. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.

    Time frame: Baseline, Week 13

  4. Change From Baseline in Clinical Dementia Rating Sum of Boxes Score (CDR-SB) at Week 13

    The CDR was developed primarily to assess severity level in persons with dementia. Six domains were assessed and then synthesized to assign a Global CDR score. The domains were memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Impairment was defined only when caused by cognitive loss rather than by physical disability or other non-cognitive factors. CDR is an ordinal parameter (scale 0 \[least impairment\]-3 \[severe impairment\]). CDR-SB score was obtained by summing each of the domain box scores, with scores ranging from 0 (least impairment) to 18 (severe impairment).

    Time frame: Baseline, Week 13

  5. Clinical Global Impression - Improvement (CGI-I) Score

    The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The Investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse.

    Time frame: Week 13

07

Results

Posted Feb 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneBPN14770 10mg BidBPN 14770 25mg BidPlacebo
Started848586
Safety population808586
Completed797984
Not completed562

Outcome measures

PrimaryChange From Baseline in Repeatable Battery for the Assessment of Neurological Status- Delayed Memory Index (RBANS- DMI) at Week 13

The RBANS is a brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory. It consists of 12 subtests, which yield 5 Index scores and a Total Scale score. Lower scores indicate worse performance on the test (and thus greater impairment). Scores for the RBANS DMI range from 40 (greater impairment) to 160 (improved function), with higher scores indicating improved function.

Time frame:
Baseline, Week 13
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Repeatable Battery for the Assessment of Neurological Status- Delayed Memory Index (RBANS- DMI) at Week 13
scores on a scaleBPN14770 10mg BidBPN 14770 25mg BidPlacebo
Change From Baseline in Repeatable Battery for the Assessment of Neurological Status- Delayed Memory Index (RBANS- DMI) at Week 1310.1 ± 1.719.9 ± 1.679.7 ± 1.63
SecondaryChange From Baseline in Repeatable Battery for the Assessment of Neurological Status (RBANS) Total Score at Week 13

The RBANS is a brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory. It consists of 12 subtests, which yield 5 Index scores and a Total Scale score. Lower scores indicate worse performance on the test (and thus greater impairment). The RBANS total score ranges from 40 to 160, with higher scores indicating improved function.

Time frame:
Baseline, Week 13
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Repeatable Battery for the Assessment of Neurological Status (RBANS) Total Score at Week 13
scores on a scaleBPN14770 10mg BidBPN 14770 25mg BidPlacebo
Change From Baseline in Repeatable Battery for the Assessment of Neurological Status (RBANS) Total Score at Week 134.5 ± 0.985.2 ± 0.965.4 ± 0.94
SecondaryChange From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Total Score at Week 13

The ADCS-ADL is an interviewer-administered informant-based scale where the informant (caregiver) responds to 23 activities of daily living questions about the participant. The questions range from basic to instrumental activities of daily living. The total score ranges from 0-78 and a higher score signifies greater functional ability.

Time frame:
Baseline, Week 13
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Total Score at Week 13
scores on a scaleBPN14770 10mg BidBPN 14770 25mg BidPlacebo
Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Total Score at Week 131.1 ± 0.551.5 ± 0.541.5 ± 0.53
SecondaryChange From Baseline in Mini-Mental State Exam (MMSE) Total Score at Week 13

The MMSE consists of 11 items covering orientation, memory (recent and immediate), concentration, language and praxis. Total score ranges from 0 (severe cognitive impairment) to 30 (intact cognitive function), with lower scores indicating greater cognitive impairment. In participants with a diagnosis of AD, lower scores indicating worse disease. A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.

Time frame:
Baseline, Week 13
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Mini-Mental State Exam (MMSE) Total Score at Week 13
scores on a scaleBPN14770 10mg BidBPN 14770 25mg BidPlacebo
Change From Baseline in Mini-Mental State Exam (MMSE) Total Score at Week 130.7 ± 0.230.8 ± 0.230.8 ± 0.23
SecondaryChange From Baseline in Clinical Dementia Rating Sum of Boxes Score (CDR-SB) at Week 13

The CDR was developed primarily to assess severity level in persons with dementia. Six domains were assessed and then synthesized to assign a Global CDR score. The domains were memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Impairment was defined only when caused by cognitive loss rather than by physical disability or other non-cognitive factors. CDR is an ordinal parameter (scale 0 \[least impairment\]-3 \[severe impairment\]). CDR-SB score was obtained by summing each of the domain box scores, with scores ranging from 0 (least impairment) to 18 (severe impairment).

Time frame:
Baseline, Week 13
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Clinical Dementia Rating Sum of Boxes Score (CDR-SB) at Week 13
scores on a scaleBPN14770 10mg BidBPN 14770 25mg BidPlacebo
Change From Baseline in Clinical Dementia Rating Sum of Boxes Score (CDR-SB) at Week 130.25 ± 0.119-0.05 ± 0.1180.19 ± 0.114
SecondaryClinical Global Impression - Improvement (CGI-I) Score

The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The Investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices included: 0=not assessed, 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse.

Time frame:
Week 13
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression - Improvement (CGI-I) Score
scores on a scaleBPN14770 10mg BidBPN 14770 25mg BidPlacebo
Clinical Global Impression - Improvement (CGI-I) Score3.5 ± 0.103.3 ± 0.103.4 ± 0.10

Adverse events

Collected over 13 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BPN14770 10mg Bid0/80 (0%)2/80 (2.5%)9/80 (11.3%)
BPN 14770 25mg Bid0/85 (0%)2/85 (2.4%)11/85 (12.9%)
Placebo0/86 (0%)2/86 (2.3%)3/86 (3.5%)
Most frequent serious events
Most frequent serious events
EventBPN14770 10mg BidBPN 14770 25mg BidPlacebo
CholecystitisHepatobiliary disorders1/800/850/86
RhabdomyolsisMusculoskeletal and connective tissue disorders1/800/850/86
PresyncopeCardiac disorders0/801/850/86
Femoral Neck FractureMusculoskeletal and connective tissue disorders0/801/850/86
DiverticulitisGastrointestinal disorders0/800/851/86
InfluenzaRespiratory, thoracic and mediastinal disorders0/800/851/86
Most frequent other events
Most frequent other events
EventBPN14770 10mg BidBPN 14770 25mg BidPlacebo
DiarrheaGastrointestinal disorders5/806/853/86
NauseaGastrointestinal disorders4/805/850/86

Baseline characteristics

Safety population included all randomized participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)BPN14770 10mg BidBPN 14770 25mg BidPlaceboTotal
Mean71.1 ± 7.5471.8 ± 7.2171.2 ± 7.6571.3 ± 7.44
Sex: Female, Male
Sex: Female, Male(Participants)BPN14770 10mg BidBPN 14770 25mg BidPlaceboTotal
Female455851154
Male35273597
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BPN14770 10mg BidBPN 14770 25mg BidPlaceboTotal
Hispanic or Latino445450148
Not Hispanic or Latino363136103
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BPN14770 10mg BidBPN 14770 25mg BidPlaceboTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American97925
White707877225
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)BPN14770 10mg BidBPN 14770 25mg BidPlaceboTotal
United States808586251
Pre Treatment MMSE
Pre Treatment MMSE(scores on a scale)BPN14770 10mg BidBPN 14770 25mg BidPlaceboTotal
Mean24.2 ± 2.0424.3 ± 2.6124.6 ± 2.4424.4 ± 2.38
08

Study locations

41 sites
  • Generations at Agritopia/CCT Research
    Gilbert, Arizona 85296, United States
  • CiTrials, Inc.
    Bellflower, California 90709, United States
  • ATP Clinical Research, Inc
    Costa Mesa, California 92626, United States
  • Alliance for Research
    Long Beach, California 90807, United States
  • Pacific Research Network Inc.
    San Diego, California 92103, United States
  • HB Clinical Trials, Inc.
    Santa Ana, California 92704, United States
  • Mile High Research Center
    Denver, Colorado 80218, United States
  • JEM Research Insitute
    Atlantis, Florida 33462, United States
  • Linfritz Research Group
    Coral Gables, Florida 33134, United States
  • Brain Matters Research
    Delray Beach, Florida 33445, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Galiz Research
    Hialeah, Florida 33016, United States
  • Alzheimer's Research and Treatement Center
    Lake Worth, Florida 33449, United States
  • Optimus Clinical Research
    Miami, Florida 33125, United States
  • BioMed Research Institute
    Miami, Florida 33126, United States
  • Finlay Medical Research
    Miami, Florida 33126, United States
  • Pharmax Research Clinic
    Miami, Florida 33126, United States
  • Vitae Research Center, LLC
    Miami, Florida 33135, United States
  • Arocha Research Center
    Miami, Florida 33145, United States
  • Allied Biomedical Research Institute Inc.
    Miami, Florida 33155, United States
  • Advanced Clinical Research Network
    Miami, Florida 33176, United States
  • Gutierrez Medical Center LLD
    Orlando, Florida 32807, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Palm Beach Neurological Center
    Palm Beach, Florida 33410, United States
  • IMIC Inc
    Palmetto Bay, Florida 33157, United States
  • Synergy Clinical Research
    Pensacola, Florida 32514, United States
  • Quantum Laboratories
    Pompano Beach, Florida 33064, United States
  • Neurosciences Research
    Elk Grove Village, Illinois 60007, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Advanced Memory Research Institute of NJ PC
    Toms River, New Jersey 08755, United States
  • Integrative Clinical Trials
    Brooklyn, New York 11229, United States
  • Neurological Associates of Long Island
    Lake Success, New York 11042, United States
  • Manhattan Behavioral Medicine PLLC
    New York, New York 10036, United States
  • Alzheimers Memory Center
    Charlotte, North Carolina 28270, United States
  • Neurology Diagnostics, Inc.
    Dayton, Ohio 45459, United States
  • MDH Research
    Westerville, Ohio 43081, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Neurology Clinic, P.C.
    Cordova, Tennessee 38018, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
  • Wasatch Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Feb 2020, 9 months.

Results were first posted in Feb 2025, 5 years after primary completion.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 9 months is below that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2019
First posted
Jan 25, 2019
StartActual
Apr 30, 2019
Primary completionActual
Feb 4, 2020
CompletionActual
Feb 4, 2020
Results first posted
Feb 18, 2025
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03817684
Responsible party
Sponsor
First posted
Jan 25, 2019
Start date
Apr 30, 2019
Primary completion
Feb 4, 2020
Completion
Feb 4, 2020
Results posted
Feb 18, 2025
Last update
Feb 18, 2025

Study contacts

Scott Reines, MD
study director · Tetra Discovery Partners

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BPN14770

Start the discussion